|Home | About | Journals | Submit | Contact Us | Français|
Left ventricular assist devices (LVADs) are being increasingly used in end-stage cardiac failures. Two-year survival rates have gone up to about 70% thanks to these devices used as a bridge for heart transplantations or destination treatment. Long survival times provided by LVAD support the increased frequency of noncardiac surgical procedures in these patients . This study presents the case of a patient who underwent LVAD insertion while waiting for heart transplantation because of dilated cardiomyopathy followed by administration of multidisciplinary treatment for rectal cancer.
The 54-year-old male patient was followed up by our hospital’s organ transplantation clinic as he developed decompensated heart failure while he was being followed up with a dilated cardiomyopathy diagnosis. As the patient’s stabilization could not be achieved by medical treatment, a HeartMate II (Thoratec Corp, Pleasanton, CA, USA) ventricular support device was inserted in order to obtain bridging to heart transplantation. Two weeks after the insertion of the HeartMate II device and the initiation of warfarin and acetyl salicylic acid (ASA) administration, a mass was detected in the mid-rectum during the colonoscopic evaluation carried out because of fresh rectal bleeding. The patient’s biopsy results revealed adenocarcinoma and his radiological evaluation indicated that it was a locally advanced stage (cT3N+) (Figure 1). The patient was taken off the transplantation waiting list. Six weeks after the patient received neoadjuvant chemoradiotherapy (CRT), the Hartmann procedure was performed under general anesthesia. The drive lines did not prevent the midline incision as shown in Figure 2. The total duration of surgery was 210 min, while the amount of measured blood loss was 240 ml. Neither intraoperative inotrope support nor blood and fresh frozen plasma transfusion was needed. The patient contracted a pelvic abscess due to rectal stump leak during the post-operative follow-up period (Figure 3). Surgical drainage was performed because percutaneous drainage and antibiotherapy failed. The patient was discharged on the 29th post-operative day. As his final pathological evaluation showed T3N2 (stage IIIC), adjuvant chemotherapy was initiated. A metastasis measuring about 3 cm was detected in hepatic segment 4A during the 25th month of follow-up (Figure 4). Although the tumor was viable for resection, the patient received radiofrequency ablation therapy because of his current comorbidity and his own preference. The patient died in the 29th month of follow-up because of multiorgan failure.
Today LVADs are being used for many patients in order to treat end-stage cardiac failures, to maintain bridging to transplantation or destination therapy. Malignity screening is recommended before implantation of these devices in an elective condition . As was the case with our patient, however, this is not always possible in cases of unexpected decompensated heart failure which is unresponsive to medical treatment. The LVAD implantation is recommended if malignancy-related survival expectancy is 2 years or more . Patients can be on a transplantation waiting list for a long time because of available organ limitation while they have LVADs and they might face non-cardiac pathologies necessitating major surgical procedures within this period. Studies, which have demonstrated that long-term survival could be rendered possible through safe abdominal surgical procedures in patients with LVADs, are encouraging [4, 5]. Despite a complex surgical procedure, surgery-related complications and CRT load, the 29-month survival in our patient, who was diagnosed with rectal cancer while he had LVAD, proved to be a long period, and his case showed parallels with stage IIIC rectal cancer cases with no comorbidities . We did not come across any other cases in the literature of patients who received multidisciplinary treatment because of rectal cancer simultaneously with LVAD.
In conclusion, possible malignancies should be detected through a comprehensive screening program in patients with end-stage heart failure before they are included on transplantation waiting lists. We believe that patients who were not included in screening programs or who contracted malignancies during the time they were living with ventricular support devices should be treated without compromising any oncological principles at centers with cardiac experience.
The authors declare no conflict of interest.